Translate Bio Inc:製薬・医療:M&Aディール及び事業提携情報

【英語タイトル】Translate Bio Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile

GlobalDataが出版した調査資料(DATA904C0496)・商品コード:DATA904C0496
・発行会社(調査会社):GlobalData
・発行日:2018年7月
・ページ数:29
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥27,250見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥54,500見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥81,750見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000を加算
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

Summary
Translate Bio Inc (Translate Bio), formerly RaNA Therapeutics Inc is a healthcare service provider that develops therapies which targets RNA within cells in the body to selectively activate protein expression. The company provides platform oligonucleotides (oligos) are molecules designed to target specific areas of RNA. Its platform uses two distinct approaches to activate RNA during transcription and post-transcription. Translate Bio provides target treatment areas such as spinal muscular atrophy and friedreich’s ataxia. It offers other target treatment areas such as musculoskeletal disease, inflammatory disease and liver disease. The company provides investment partners such as Atlas Venture, Monsanto, MS Ventures, Omega Funds, Partners Innovation Fund, Pfizer Venture Investments and SR One, among others. Translate Bio is headquartered in Lexington, Massachusetts, the US.

Translate Bio Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Translate Bio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Translate Bio Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Translate Bio Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Translate Bio Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Translate Bio Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Translate Bio Inc, Pharmaceuticals & Healthcare, Deal Details 10
Asset Purchase 10
RaNA Therapeutics Acquires MRT Platform from Shire 10
Translate Bio to Acquire mRNA Therapy Platform from Shire Human Genetic Therapies 11
Venture Financing 12
RaNA Therapeutics Raises USD51 million in Venture Financing 12
Translate Bio Raises USD51 Million in Venture Financing 13
RaNA Therapeutics Raises USD55 Million in series B Financing 14
RaNA Therapeutics Raises Additional US$18 Million In Series A Financing 15
Licensing Agreements 17
Sanofi Pasteur Enters into Licensing Agreement with Translate Bio 17
RaNA Therapeutics Enters Into Licensing Agreement With Santaris Pharma To Develop RNA-Targeted Medicines 18
Equity Offering 19
Translate Bio Prices IPO of Shares for USD121.6 Million 19
Translate Bio Raises USD42 Million in Private Placement of Preferred Shares 20
Translate Bio Inc – Key Competitors 21
Translate Bio Inc – Key Employees 22
Translate Bio Inc – Locations And Subsidiaries 23
Head Office 23
Recent Developments 24
Corporate Communications 24
May 23, 2018: Translate Bio Appoints John R. Schroer As Chief Financial Officer 24
Nov 06, 2017: Translate Bio Appoints Ann Barbier, M.D., Ph.D., as Chief Medical Officer 25
Oct 04, 2017: Translate Bio Names Daniella Beckman to Board of Directors 26
Product Approvals 27
Apr 12, 2018: Translate Bio Announces FDA Clearance to Proceed with Phase 1/2 Clinical Trial in Patients with Cystic Fibrosis (CF) 27
Other Significant Developments 28
Jun 27, 2017: RaNA Therapeutics Relaunches as Translate Bio to Advance RNA Therapeutics 28
Appendix 29
Methodology 29
About GlobalData 29
Contact Us 29
Disclaimer 29

List of Tables
Translate Bio Inc, Pharmaceuticals & Healthcare, Key Facts 2
Translate Bio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Translate Bio Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Translate Bio Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Translate Bio Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Translate Bio Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
RaNA Therapeutics Acquires MRT Platform from Shire 10
Translate Bio to Acquire mRNA Therapy Platform from Shire Human Genetic Therapies 11
RaNA Therapeutics Raises USD51 million in Venture Financing 12
Translate Bio Raises USD51 Million in Venture Financing 13
RaNA Therapeutics Raises USD55 Million in series B Financing 14
RaNA Therapeutics Raises Additional US$18 Million In Series A Financing 15
Sanofi Pasteur Enters into Licensing Agreement with Translate Bio 17
RaNA Therapeutics Enters Into Licensing Agreement With Santaris Pharma To Develop RNA-Targeted Medicines 18
Translate Bio Prices IPO of Shares for USD121.6 Million 19
Translate Bio Raises USD42 Million in Private Placement of Preferred Shares 20
Translate Bio Inc, Key Competitors 21
Translate Bio Inc, Key Employees 22

List of Figures
Translate Bio Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Translate Bio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Translate Bio Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Translate Bio Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Translate Bio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Translate Bio Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Translate Bio Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Translate Bio Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★調査レポート[Translate Bio Inc:製薬・医療:M&Aディール及び事業提携情報] (コード:DATA904C0496)販売に関する免責事項を必ずご確認ください。
★調査レポート[Translate Bio Inc:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆